Cancer Gene Therapy Market Report Scope & Overview:
The cancer gene therapy market size was valued at USD 4.07 billion in 2024 and is expected to reach USD 17.35 billion by 2032, growing at a CAGR of 19.96% over the forecast period of 2025-2032.
The global cancer gene therapy market is growing rapidly due to the growing gene engineering research, the increasing number of approved CAR-T and other gene-targeted therapies, and the increasing global incidence of cancer. The movement toward precision medicine, coupled with its specific relevance to personalized cancer therapy, is rapidly expanding the gene-based treatment of hematologic malignancies. The cancer gene therapy market growth is also supported by ongoing clinical trials, possible strategic collaborations, and increasing capacity. The transformation of cancer therapy through gene therapy is just around the corner, with increasing regulatory support and advancements in gene delivery technologies.
The U.S. cancer gene therapy market size was valued at USD 1.95 billion in 2024 and is expected to reach USD 8.30 billion by 2032, growing at a CAGR of 19.90% over the forecast period of 2025-2032.
North America cancer gene therapy market is led by the U.S., owing to better ecosystems for clinical trials, research & development higher number of key biotech and generic drug companies. It is the birthplace of multiple FDA-approved gene therapies and is well-funded through federal agencies such as the NIH and NCI, enabling further innovations and speed to market of new cancer gene therapies.
Market Dynamics:
Drivers
-
Increase In the Incidence of Cancer Globally, Fuelling the Market Growth
The growing global incidence of cancer due to an aging population, environmental, and other risk factors related to lifestyle, has created a large market for new treatments. Traditional therapies (i.e., chemo and radiation) are limited by significant side effects and resistance. An emerging alternative is gene therapy, which has the potential to treat the underlying disease at the genetic level and may be a more precise and effective means of treatment. As a result, healthcare systems and biotech firms are pouring funds into gene-based solutions to combat this explosion in the prevalence of cancer.
According to WHO estimates in 2022, there were approximately 20 million new cases of cancer and 9.7 million cancer deaths. By this measure, an estimated 53.5 million people were alive within 5 years of a cancer diagnosis. One out of five people develops cancer within their lifetime, 1within 9 men and 1in 12 women die of the disease.
-
Advancements in Gene Editing and Vector Technologies are Accelerating the Market Growth
The invention of powerful gene editing tools such as CRISPR-Cas9 and TALENs, as well as enhanced viral vector systems including lentivirus and AAV, has enhanced the therapeutic promise of cancer gene therapy. Consequently, these innovations have enabled advances in specificity, safety, and stability for gene delivery, which can lead to more personalized and durable cancer therapies. This technological advancement is a key enabler for moving gene therapy use beyond rare cancers into common and more complex malignancies.
There are more than 100 CRISPR clinical trials, which have grown rapidly, as CRISPR Medicine News reported that a total of 98 were recorded worldwide by April 2025.
Restraint
-
High Cost of Treatment and Limited Accessibility Restraining the Market from Growth
High cost of treatment is one of the major limiting, restraining factors in the Cancer Gene Therapy Market. Certain gene therapies, such as CAR-T cell therapies, can range from USD 350,000 to more than USD 500,000 per patient, excluding the cost of hospital stays, supportive care, or other procedures. These are highly complicated to manufacture, often made to order for patients, which may require special facilities and highly skilled workers, all of which contribute to the cost. That means it is only available to well-heeled health systems in wealthy areas. Affordable prices and appropriate reimbursement frameworks for low- and middle-income countries are critically necessary to ensure patient access and grow the global market; lack of these critical enablers is raising several equity issues in cancer care.
Segmentation Analysis:
By Indication
In 2024, the cancer gene therapy market share was led by the large B-cell lymphoma segment with a 54.26%, as a result of the successful launch and uptake of CAR-T cell therapies targeted against these indications. Therapies such as Yescarta and Breyanzi have demonstrated major clinical effectiveness and been approved by regulators in dozens of countries, resulting in their widespread utilization in relapsed or refractory settings. Moreover, the increasing availability of treatment facilities capable of delivering gene-based therapies and better reimbursement policies have further facilitated the adoption of these therapies in Large B-Cell Lymphoma.
During the forecast period, the other segment, which encompasses solid tumors, glioblastoma, pancreatic cancer, and other forms of malignancies, is expected to grow at the highest CAGR. Research expansion in the potential applications of gene therapy beyond hematological cancers is driving this growth, along with the increase in clinical trials and innovations in gene delivery systems, leading to increased competition among the major players during the considered period. Increasing interest in personalized and precision medicine is drawing companies to consider more novel vectors and gene-editing approaches for cancers thought to be untreatable or that have become resistant to all known therapies, which provides continued impetus for this diverse and dynamic segment of the commercial focus area.
By Route of Administration
In 2024, the Intravenous segment held the largest share of the cancer gene therapy market with 91.25% due to intravenous being the traditional and most prominent route of delivery for existing gene therapies, particularly CAR-T cell and viral vector-based therapies. This ensures fast introduction into the body, where the targeted cancer cells can be quickly populated with the new cells or genetic material. Hospital and oncology practices often favor IV delivery given its representable and clinically familiar performance coupled with the potential for finer control of dosing via infusion-based therapies. The intravenous segment is also expected to grow at the fastest pace during the forecast period; continuous advances in gene therapy have yet to sway the route of administration from IV, as the pipeline of new-generation therapies remains concentrated on this route. As more IV-administered gene therapies gain approvals and more infusion centers develop their infrastructures, the IV route is anticipated to grow rapidly both in developing and developed markets.
By Vector Type
Lentivirus segment dominated the cancer gene therapy market in 2024 with a 46.18% market share, as it has been the key technology for ex vivo gene therapies, particularly CAR-T cell therapies in hematologic cancers such as large B-cell lymphoma and acute lymphoblastic leukemia. Lentiviral vectors are preferred to deliver transgenes, as they can integrate stably in the host genome, allowing for long-lasting expression of therapeutic genes. Adenoviruses are the most commonly used vector type in current cancer gene therapy applications due to their safety profile, ability to carry large genetic payloads, and successful track record across multiple approved therapies.
The AAV segment is estimated to be the fastest-growing vector-based market during the forecast period, as innovators are targeting breakthroughs in solid tumors and in vivo gene therapy. They also exhibit low immunogenicity, the ability to infect dividing and non-dividing cells, and integration into the host genome is minimal, making AAV vectors safer for clinical purposes in the long term. As the need to directly target tumors becomes more and more present across a wide array of different cancer types, the increasingly significant and fast uptake of tumor-infiltrating T cell therapies in preclinical and clinical trials in more and more tissue types will lead to a broader range of cancer indications undergoing rapid development shortly.
By End User
The cancer research institute's segment dominated the cancer gene therapy market with a 74.5% market share due to that they are significant contributors to research in the advancement, testing, and science of natural and artificial cancer treatments. These institutes are first-movers in early-phase clinical trials, academia-industry synergies, and cancer translational research. Armed with state-of-the-art technologies, ample funding from both governmental and private sector sources, they become the poster children for CAR-T cell therapy, biomanufacturing, gene editing, and viral vector development, the leaders of the gene therapeutic ecosystem.
The others (hospitals and biotechnology companies) segment is predicted to grow at the highest CAGR during the forecast period due to the commercialization of approved gene therapies and hospital-based administration. Hospitals gear up for stores of compounding gene therapy; biotechs up production, speed clinical pipelines to late-stage. Increasing research-translational adoption, expanding reach to patients, and investment dollars for infrastructure and commercialization strategies will contribute to solid tumor growth as more gene therapies progress past research settings into mainstream cancer treatment.
Regional Analysis:
The cancer gene therapy market is dominated by North America, with 63.11% market share in 2024, driven by the highly evolved biotechnology ecosystem in this region, the presence of leading gene therapy developers, and early regulatory approvals of path-breaking therapies, including CAR-T cell therapies. This region benefits from significant public as well as private investment in precision oncology, strong clinical research infrastructure, and a high level of awareness among healthcare professionals and patients. The U.S. is helping the development of the ever-growing list of breakthrough therapies with fee-waived FDA-backed priority review, allowing a relatively rapid pathway to state-of-the-art commercialization and implementation of novel cancer gene therapies.
The cancer gene therapy market analysis in Asia Pacific is growing at a significant rate, followed by North America, as there is a large patient population growing rapidly, a high number of cancer cases are being registered, with high investment in genomics and biopharmaceuticals. Governments from countries such as China, Japan, and South Korea are building up their clinical trial infrastructure—and stimulating home-grown biotech innovation—through a combination of public funding and regulatory changes. As Asia Pacific continues to turn into a notable development center for cancer gene treatment arrangements, it is likely to benefit from expanded access to healthcare services, the developing recognition of precision medicine, and key coordinated efforts between the local and global players.
The cancer gene therapy market in Europe is growing substantially due to the most public–private research efforts, along with favorable regulatory agreements. Innovation is thus being encouraged, and the pace of gene-based cancer therapies is being accelerated thanks to various programs such as the European Union's Horizon Europe Mission on Cancer. Europe is a growing hub for the development of cancer gene therapy, generating a strong pipeline of applications through increasing numbers of clinical trials, broadening biomanufacturing capability, and partnerships between biotech companies and academic institutions.
The mission "Horizon Europe Mission on Cancer" was launched in Sept 2023 and includes an integrative research, public health, and citizen engagement approach towards translating cancer therapeutics innovation into the betterment of the lives of those affected by cancer.
Latin America, expected to experience moderate growth in the market. The cancer gene therapy market trends are due to the growing clinical trials in Latin America, which will gain better infrastructural access to medical resources and increase adoption of oncolytic virotherapy in this region, resulting in high growth prospects. The growth region is expected to grow at a moderate rate through the forecast period.
MEA is experiencing the gradual progression over the forecast period driven by investment into gene therapy platforms, manufacturing services, and domestic regulatory reform. Progressing through active market development, the leading markets such as South Africa, Saudi Arabia, and the UAE that were more concerned with segment-oriented testing are now more concentrated on oncology genomics and CAR-T.
Key Players
The cancer gene therapy market companies, OncoGenex Pharmaceuticals Inc., Merck KGaA, Introgen Therapeutics Inc., GSK plc (GlaxoSmithKline), GenVec, Genelux Corporation, Elevate Bio Inc., Celgene Inc., Bluebird Bio Inc., BioCancell Inc., and other players.
Recent Developments
-
May 2025 – Merck KGaA announced encouraging data from the clinic to justify its $85 million upfront investment in a late-phase tenosynovial giant cell tumor (TGCT) therapy; TGCT is a rare, locally aggressive tumor. As Merck gets primed to face off against Daiichi Sankyo and Ono Pharmaceutical over the TGCT treatment battleground, the data drop positions it.
-
January 2025 — GSK plc announced the acquisition of IDRx, Inc., a clinical-stage Boston-based biopharmaceutical company developing precision therapeutics for GISTs. The upfront consideration consists of an immediate cash payment of US$1 billion and a further USD150 million contingent on regulatory milestones being achieved. The acquisition gives GSK lead asset IDRX-42, a highly selective KIT TKI in development for first- and second-line GIST treatment.
| Report Attributes | Details |
|---|---|
| Market Size in 2024 | USD 4.07 Billion |
| Market Size by 2032 | USD 17.35 Billion |
| CAGR | CAGR of 19.96% From 2025 to 2032 |
| Base Year | 2024 |
| Forecast Period | 2025-2032 |
| Historical Data | 2021-2023 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Indication (Large B-Cell Lymphoma, Multiple Myeloma, Acute Lymphoblastic Leukemia (ALL), Melanoma (lesions), Others) • By Route of Administration (Intravenous, Others) • By Vector Type (Lentivirus, Retrovirus & Gamma Retrovirus, AAV, Modified Herpes Simplex Virus, Adenovirus, Others) • By End User (Cancer Research Institutes, Diagnostic Centers, Others [Hospitals and Biotechnology Companies]) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, Poland, Turkey, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) |
| Company Profiles | OncoGenex Pharmaceuticals Inc., Merck KGaA, Introgen Therapeutics Inc., GSK plc (GlaxoSmithKline), GenVec, Genelux Corporation, Elevate Bio Inc., Celgene Inc., Bluebird Bio Inc., BioCancell Inc., and other players. |
Table Of Content
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 Cancer Incidence and Prevalence (2024)
5.2 Gene Therapy Clinical Pipeline and Approvals (2024)
5.3 Adoption Trends by Therapy Type and Region (2020–2032)
5.4 Precision Oncology Prescription Patterns (2024)
5.5 Manufacturing & Supply Chain Capacity (2020–2032)
6. Competitive Landscape
6.1 List of Major Companies By Region
6.2 Market Share Analysis By Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and Supply Chain Strategies
6.4.3 Expansion plans and new product launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. Cancer Gene Therapy Market Segmentation By Indication
7.1 Chapter Overview
7.2 Large B-Cell Lymphoma
7.2.1 Large B-Cell Lymphoma Market Trends Analysis (2021-2032)
7.2.2 Large B-Cell Lymphoma Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3 Multiple Myeloma
7.3.1 Multiple Myeloma Market Trends Analysis (2021-2032)
7.3.2 Multiple Myeloma Market Size Estimates and Forecasts to 2032 (USD Billion)
7.4 Acute Lymphoblastic Leukemia (ALL)
7.4.1 Acute Lymphoblastic Leukemia (ALL) Market Trends Analysis (2021-2032)
7.4.2 Acute Lymphoblastic Leukemia (ALL) Market Size Estimates and Forecasts to 2032 (USD Billion)
7.5 Melanoma (lesions)
7.5.1 Melanoma (lesions) Market Trends Analysis (2021-2032)
7.5.2 Melanoma (lesions) Market Size Estimates and Forecasts to 2032 (USD Billion)
7.6 Others
7.6.1 Others Market Trends Analysis (2021-2032)
7.6.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
8. Cancer Gene Therapy Market Segmentation By Route of Administration
8.1 Chapter Overview
8.2 Intravenous
8.2.1 Intravenous Market Trends Analysis (2021-2032)
8.2.2 Intravenous Market Size Estimates and Forecasts to 2032 (USD Billion)
8.3 Others
8.3.1 Others Market Trends Analysis (2021-2032)
8.3.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
9. Cancer Gene Therapy Market Segmentation By Vector Type
9.1 Chapter Overview
9.2 Lentivirus
9.2.1 Lentivirus Market Trends Analysis (2021-2032)
9.2.2 Lentivirus Market Size Estimates and Forecasts to 2032 (USD Billion)
9.3 RetroVirus & gamma RetroVirus
9.3.1 RetroVirus & gamma RetroVirus Market Trends Analysis (2021-2032)
9.3.2 RetroVirus & gamma RetroVirus Market Size Estimates and Forecasts to 2032 (USD Billion)
9.3 AAV
9.3.1 AAV Market Trends Analysis (2021-2032)
9.3.2 AAV Market Size Estimates and Forecasts to 2032 (USD Billion)
9.3 Modified Herpes Simplex Virus
9.3.1 Modified Herpes Simplex Virus Market Trends Analysis (2021-2032)
9.3.2 Modified Herpes Simplex Virus Market Size Estimates and Forecasts to 2032 (USD Billion)
9.3 Adenovirus
9.3.1 Adenovirus Market Trends Analysis (2021-2032)
9.3.2 Adenovirus Market Size Estimates and Forecasts to 2032 (USD Billion)
9.3 Others
9.3.1 Others Market Trends Analysis (2021-2032)
9.3.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
10. Cancer Gene Therapy Market Segmentation by End-User
10.1 Chapter Overview
10.2 Cancer Research Institutes
10.2.1 Cancer Research Institutes Market Trends Analysis (2021-2032)
10.2.2 Cancer Research Institutes Market Size Estimates and Forecasts to 2032 (USD Billion)
10.3 Diagnostic Centers
10.3.1 Diagnostic Centers Market Trend Analysis (2021-2032)
10.3.2 Diagnostic Centers Market Size Estimates and Forecasts to 2032 (USD Billion)
10.4 Others (Hospitals and biotechnology Companies)
10.4.1 Others (Hospitals and biotechnology Companies) Market Trends Analysis (2021-2032)
10.4.2 Others (Hospitals and biotechnology Companies) Market Size Estimates and Forecasts to 2032 (USD Billion)
11. Regional Analysis
11.1 Chapter Overview
11.2 North America
11.2.1 Trend Analysis
11.2.2 North America Cancer Gene Therapy Market Estimates and Forecasts by Country (2021-2032) (USD Billion)
11.2.3 North America Cancer Gene Therapy Market Estimates and Forecasts by Indication (2021-2032) (USD Billion)
11.2.4 North America Cancer Gene Therapy Market Estimates and Forecasts by Route of Administration (2021-2032) (USD Billion)
11.2.5 North America Cancer Gene Therapy Market Estimates and Forecasts by Vector Type (2021-2032) (USD Billion)
11.2.6 North America Cancer Gene Therapy Market Estimates and Forecasts by End-User (2021-2032) (USD Billion)
11.2.7 USA
11.2.7.1 USA Cancer Gene Therapy Market Estimates and Forecasts by Indication (2021-2032) (USD Billion)
11.2.7.2 USA Cancer Gene Therapy Market Estimates and Forecasts by Route of Administration (2021-2032) (USD Billion)
11.2.7.3 USA Cancer Gene Therapy Market Estimates and Forecasts by Vector Type (2021-2032) (USD Billion)
11.2.7.4 USA Cancer Gene Therapy Market Estimates and Forecasts by End-User (2021-2032) (USD Billion)
11.2.8 Canada
11.2.8.1 Canada Cancer Gene Therapy Market Estimates and Forecasts by Indication (2021-2032) (USD Billion)
11.2.8.2 Canada Cancer Gene Therapy Market Estimates and Forecasts by Route of Administration (2021-2032) (USD Billion)
11.2.8.3 Canada Cancer Gene Therapy Market Estimates and Forecasts by Vector Type (2021-2032) (USD Billion)
11.2.8.4 Canada Cancer Gene Therapy Market Estimates and Forecasts by End-User (2021-2032) (USD Billion)
11.2.9 Mexico
11.2.9.1 Mexico Cancer Gene Therapy Market Estimates and Forecasts by Indication (2021-2032) (USD Billion)
11.2.9.2 Mexico Cancer Gene Therapy Market Estimates and Forecasts by Route of Administration (2021-2032) (USD Billion)
11.2.9.3 Mexico Cancer Gene Therapy Market Estimates and Forecasts by Vector Type (2021-2032) (USD Billion)
11.2.9.4 Mexico Cancer Gene Therapy Market Estimates and Forecasts by End-User (2021-2032) (USD Billion)
11.3 Europe
11.3.1 Trend Analysis
11.3.2 Europe Cancer Gene Therapy Market Estimates and Forecasts by Country (2021-2032) (USD Billion)
11.3.3 Europe Cancer Gene Therapy Market Estimates and Forecasts by Indication (2021-2032) (USD Billion)
11.3.4 Europe Cancer Gene Therapy Market Estimates and Forecasts by Route of Administration (2021-2032) (USD Billion)
11.3.5 Europe Cancer Gene Therapy Market Estimates and Forecasts by Vector Type (2021-2032) (USD Billion)
11.3.6 Europe Cancer Gene Therapy Market Estimates and Forecasts by End-User (2021-2032) (USD Billion)
11.3.7 Germany
11.3.7.1 Germany Cancer Gene Therapy Market Estimates and Forecasts by Indication (2021-2032) (USD Billion)
11.3.7.2 Germany Cancer Gene Therapy Market Estimates and Forecasts by Route of Administration (2021-2032) (USD Billion)
11.3.7.3 Germany Cancer Gene Therapy Market Estimates and Forecasts by Vector Type (2021-2032) (USD Billion)
11.3.7.4 Germany Cancer Gene Therapy Market Estimates and Forecasts by End-User (2021-2032) (USD Billion)
11.3.8 France
11.3.8.1 France Cancer Gene Therapy Market Estimates and Forecasts by Indication (2021-2032) (USD Billion)
11.3.8.2 France Cancer Gene Therapy Market Estimates and Forecasts by Route of Administration (2021-2032) (USD Billion)
11.3.8.3 France Cancer Gene Therapy Market Estimates and Forecasts by Vector Type (2021-2032) (USD Billion)
11.3.8.4 France Cancer Gene Therapy Market Estimates and Forecasts by End-User (2021-2032) (USD Billion)
11.3.9 UK
11.3.9.1 UK Cancer Gene Therapy Market Estimates and Forecasts by Indication (2021-2032) (USD Billion)
11.3.9.2 UK Cancer Gene Therapy Market Estimates and Forecasts by Route of Administration (2021-2032) (USD Billion)
11.3.9.3 UK Cancer Gene Therapy Market Estimates and Forecasts by Vector Type (2021-2032) (USD Billion)
11.3.9.4 UK Cancer Gene Therapy Market Estimates and Forecasts by End-User (2021-2032) (USD Billion)
11.3.10 Italy
11.3.10.1 ItalyCancer Gene Therapy Market Estimates and Forecasts by Indication (2021-2032) (USD Billion)
11.3.10.2 Italy Cancer Gene Therapy Market Estimates and Forecasts by Route of Administration (2021-2032) (USD Billion)
11.3.10.3 Italy Cancer Gene Therapy Market Estimates and Forecasts by Vector Type (2021-2032) (USD Billion)
11.3.10.4 Italy Cancer Gene Therapy Market Estimates and Forecasts by End-User (2021-2032) (USD Billion)
11.3.11 Spain
11.3.11.1 Spain Cancer Gene Therapy Market Estimates and Forecasts by Indication (2021-2032) (USD Billion)
11.3.11.2 Spain Cancer Gene Therapy Market Estimates and Forecasts by Route of Administration (2021-2032) (USD Billion)
11.3.11.3 Spain Cancer Gene Therapy Market Estimates and Forecasts by Vector Type (2021-2032) (USD Billion)
11.3.11.4 Spain Cancer Gene Therapy Market Estimates and Forecasts by End-User (2021-2032) (USD Billion)
11.3.12 Poland
11.3.12.1 Poland Cancer Gene Therapy Market Estimates and Forecasts by Indication (2021-2032) (USD Billion)
11.3.12.2 Poland Cancer Gene Therapy Market Estimates and Forecasts by Route of Administration (2021-2032) (USD Billion)
11.3.12.3 Poland Cancer Gene Therapy Market Estimates and Forecasts by Vector Type (2021-2032) (USD Billion)
11.3.12.4 Poland Cancer Gene Therapy Market Estimates and Forecasts by End-User (2021-2032) (USD Billion)
11.3.13 Turkey
11.3.13.1 Turkey Cancer Gene Therapy Market Estimates and Forecasts by Indication (2021-2032) (USD Billion)
11.3.13.2 Turkey Cancer Gene Therapy Market Estimates and Forecasts by Route of Administration (2021-2032) (USD Billion)
11.3.13.3 Turkey Cancer Gene Therapy Market Estimates and Forecasts by Vector Type (2021-2032) (USD Billion)
11.3.13.4 Turkey Cancer Gene Therapy Market Estimates and Forecasts by End-User (2021-2032) (USD Billion)
11.3.14 Rest of Europe
11.3.14.1 Rest of Europe Cancer Gene Therapy Market Estimates and Forecasts by Indication (2021-2032) (USD Billion)
11.3.14.2 Rest of Europe Cancer Gene Therapy Market Estimates and Forecasts by Route of Administration (2021-2032) (USD Billion)
11.3.14.3 Rest of Europe Cancer Gene Therapy Market Estimates and Forecasts by Vector Type (2021-2032) (USD Billion)
11.3.14.4 Rest of Europe Cancer Gene Therapy Market Estimates and Forecasts by End-User (2021-2032) (USD Billion)
11.4 Asia Pacific
11.4.1 Trend Analysis
11.4.2 Asia Pacific Cancer Gene Therapy Market Estimates and Forecasts by Country (2021-2032) (USD Billion)
11.4.3 Asia Pacific Cancer Gene Therapy Market Estimates and Forecasts by Indication (2021-2032) (USD Billion)
11.4.4 Asia Pacific Cancer Gene Therapy Market Estimates and Forecasts by Route of Administration (2021-2032) (USD Billion)
11.4.5 Asia Pacific Cancer Gene Therapy Market Estimates and Forecasts by Vector Type (2021-2032) (USD Billion)
11.4.6 Asia Pacific Cancer Gene Therapy Market Estimates and Forecasts by End-User (2021-2032) (USD Billion)
11.4.7 China
11.4.7.1 China Cancer Gene Therapy Market Estimates and Forecasts by Indication (2021-2032) (USD Billion)
11.4.7.2 China Cancer Gene Therapy Market Estimates and Forecasts by Route of Administration (2021-2032) (USD Billion)
11.4.7.3 China Cancer Gene Therapy Market Estimates and Forecasts by Vector Type (2021-2032) (USD Billion)
11.4.7.4 China Cancer Gene Therapy Market Estimates and Forecasts by End-User (2021-2032) (USD Billion)
11.4.8 India
11.4.8.1 India Cancer Gene Therapy Market Estimates and Forecasts by Indication (2021-2032) (USD Billion)
11.4.8.2 India Cancer Gene Therapy Market Estimates and Forecasts by Route of Administration (2021-2032) (USD Billion)
11.4.8.3 India Cancer Gene Therapy Market Estimates and Forecasts by Vector Type (2021-2032) (USD Billion)
11.4.8.4 India Cancer Gene Therapy Market Estimates and Forecasts by End-User (2021-2032) (USD Billion)
11.4.9 Japan
11.4.9.1 Japan Cancer Gene Therapy Market Estimates and Forecasts by Indication (2021-2032) (USD Billion)
11.4.9.2 Japan Cancer Gene Therapy Market Estimates and Forecasts by Route of Administration (2021-2032) (USD Billion)
11.4.9.3 Japan Cancer Gene Therapy Market Estimates and Forecasts by Vector Type (2021-2032) (USD Billion)
11.4.9.4 Japan Cancer Gene Therapy Market Estimates and Forecasts by End-User (2021-2032) (USD Billion)
11.4.10 South Korea
11.4.10.1 South Korea Cancer Gene Therapy Market Estimates and Forecasts by Indication (2021-2032) (USD Billion)
11.4.10.2 South Korea Cancer Gene Therapy Market Estimates and Forecasts by Route of Administration (2021-2032) (USD Billion)
11.4.10.3 South Korea Cancer Gene Therapy Market Estimates and Forecasts by Vector Type (2021-2032) (USD Billion)
11.4.10.4 South Korea Cancer Gene Therapy Market Estimates and Forecasts by End-User (2021-2032) (USD Billion)
11.4.11 Singapore
11.4.11.1 Singapore Cancer Gene Therapy Market Estimates and Forecasts by Indication (2021-2032) (USD Billion)
11.4.11.2 Singapore Cancer Gene Therapy Market Estimates and Forecasts by Route of Administration (2021-2032) (USD Billion)
11.4.11.3 Singapore Cancer Gene Therapy Market Estimates and Forecasts by Vector Type (2021-2032) (USD Billion)
11.4.11.4 Singapore Cancer Gene Therapy Market Estimates and Forecasts by End-User (2021-2032) (USD Billion)
11.4.12 Australia
11.4.12.1 Australia Cancer Gene Therapy Market Estimates and Forecasts by Indication (2021-2032) (USD Billion)
11.4.12.2 Australia Cancer Gene Therapy Market Estimates and Forecasts by Route of Administration (2021-2032) (USD Billion)
11.4.12.3 Australia Cancer Gene Therapy Market Estimates and Forecasts by Vector Type (2021-2032) (USD Billion)
11.4.12.4 Australia Cancer Gene Therapy Market Estimates and Forecasts by End-User (2021-2032) (USD Billion)
11.4.13 Rest of Asia Pacific
11.4.13.1 Rest of Asia Pacific Cancer Gene Therapy Market Estimates and Forecasts by Indication (2021-2032) (USD Billion)
11.4.13.2 Rest of Asia Pacific Cancer Gene Therapy Market Estimates and Forecasts by Route of Administration (2021-2032) (USD Billion)
11.4.13.3 Rest of Asia Pacific Cancer Gene Therapy Market Estimates and Forecasts by Vector Type (2021-2032) (USD Billion)
11.4.13.4 Rest of Asia Pacific Cancer Gene Therapy Market Estimates and Forecasts by End-User (2021-2032) (USD Billion)
11.5 Middle East and Africa
11.5.1 Trend Analysis
11.5.2 Middle East and Africa Cancer Gene Therapy Market Estimates and Forecasts by Country (2021-2032) (USD Billion)
11.5.3 Middle East and Africa Cancer Gene Therapy Market Estimates and Forecasts by Indication (2021-2032) (USD Billion)
11.5.4 Middle East and Africa Cancer Gene Therapy Market Estimates and Forecasts by Route of Administration (2021-2032) (USD Billion)
11.5.5 Middle East and Africa Cancer Gene Therapy Market Estimates and Forecasts by Vector Type (2021-2032) (USD Billion)
11.5.6 Middle East and Africa Cancer Gene Therapy Market Estimates and Forecasts by End-User (2021-2032) (USD Billion)
11.5.7 UAE
11.5.7.1 UAE Cancer Gene Therapy Market Estimates and Forecasts by Indication (2021-2032) (USD Billion)
11.5.7.2 UAE Cancer Gene Therapy Market Estimates and Forecasts by Route of Administration (2021-2032) (USD Billion)
11.5.7.3 UAE Cancer Gene Therapy Market Estimates and Forecasts by Vector Type (2021-2032) (USD Billion)
11.5.7.4 UAE Cancer Gene Therapy Market Estimates and Forecasts by End-User (2021-2032) (USD Billion)
11.5.8 Saudi Arabia
11.5.8.1 Saudi Arabia Cancer Gene Therapy Market Estimates and Forecasts by Indication (2021-2032) (USD Billion)
11.5.8.2 Saudi Arabia Cancer Gene Therapy Market Estimates and Forecasts by Route of Administration (2021-2032) (USD Billion)
11.5.8.3 Saudi Arabia Cancer Gene Therapy Market Estimates and Forecasts by Vector Type (2021-2032) (USD Billion)
11.5.8.4 Saudi Arabia Cancer Gene Therapy Market Estimates and Forecasts by End-User (2021-2032) (USD Billion)
11.5.9 Qatar
11.5.9.1 Qatar Cancer Gene Therapy Market Estimates and Forecasts by Indication (2021-2032) (USD Billion)
11.5.9.2 Qatar Cancer Gene Therapy Market Estimates and Forecasts by Route of Administration (2021-2032) (USD Billion)
11.5.9.3 Qatar Cancer Gene Therapy Market Estimates and Forecasts by Vector Type (2021-2032) (USD Billion)
11.5.1.9.4 Qatar Cancer Gene Therapy Market Estimates and Forecasts by End-User (2021-2032) (USD Billion)
11.5.10 South Africa
11.5.10.1 South Africa Cancer Gene Therapy Market Estimates and Forecasts by Indication (2021-2032) (USD Billion)
11.5.10.2 South Africa Cancer Gene Therapy Market Estimates and Forecasts by Route of Administration (2021-2032) (USD Billion)
11.5.10.3 South Africa Cancer Gene Therapy Market Estimates and Forecasts by Vector Type (2021-2032) (USD Billion)
11.5.10.4 South Africa Cancer Gene Therapy Market Estimates and Forecasts by End-User (2021-2032) (USD Billion)
11.5.11 Rest of Middle East & Africa
11.5.11.1 Rest of Middle East & Africa Cancer Gene Therapy Market Estimates and Forecasts by Indication (2021-2032) (USD Billion)
11.5.11.2 Rest of Middle East & Africa Cancer Gene Therapy Market Estimates and Forecasts by Route of Administration (2021-2032) (USD Billion)
11.5.11.3 Rest of Middle East & Africa Cancer Gene Therapy Market Estimates and Forecasts by Vector Type (2021-2032) (USD Billion)
11.5.11.4 Rest of Middle East & Africa Cancer Gene Therapy Market Estimates and Forecasts by End-User (2021-2032) (USD Billion)
11.6 Latin America
11.6.1 Trend Analysis
11.6.2 Latin America Cancer Gene Therapy Market Estimates and Forecasts by Country (2021-2032) (USD Billion)
11.6.3 Latin America Cancer Gene Therapy Market Estimates and Forecasts by Indication (2021-2032) (USD Billion)
11.6.4 Latin America Cancer Gene Therapy Market Estimates and Forecasts by Route of Administration (2021-2032) (USD Billion)
11.6.5 Latin America Cancer Gene Therapy Market Estimates and Forecasts by Vector Type (2021-2032) (USD Billion)
11.6.6 Latin America Cancer Gene Therapy Market Estimates and Forecasts by End-User (2021-2032) (USD Billion)
11.6.7 Brazil
11.6.7.1 Brazil Cancer Gene Therapy Market Estimates and Forecasts by Indication (2021-2032) (USD Billion)
11.6.7.2 Brazil Cancer Gene Therapy Market Estimates and Forecasts by Route of Administration (2021-2032) (USD Billion)
11.6.7.3 Brazil Cancer Gene Therapy Market Estimates and Forecasts by Vector Type (2021-2032) (USD Billion)
11.6.7.4 Brazil Cancer Gene Therapy Market Estimates and Forecasts by End-User (2021-2032) (USD Billion)
11.6.8 Argentina
11.6.8.1 Argentina Cancer Gene Therapy Market Estimates and Forecasts by Indication (2021-2032) (USD Billion)
11.6.8.2 Argentina Cancer Gene Therapy Market Estimates and Forecasts by Route of Administration (2021-2032) (USD Billion)
11.6.8.3 Argentina Cancer Gene Therapy Market Estimates and Forecasts by Vector Type (2021-2032) (USD Billion)
11.6.8.4 Argentina Cancer Gene Therapy Market Estimates and Forecasts by End-User (2021-2032) (USD Billion)
11.6.9 Rest of Latin America
11.6.9.1 Rest of Latin America Cancer Gene Therapy Market Estimates and Forecasts by Indication (2021-2032) (USD Billion)
11.6.9.2 Rest of Latin America Cancer Gene Therapy Market Estimates and Forecasts by Route of Administration (2021-2032) (USD Billion)
11.6.9.3 Rest of Latin America Cancer Gene Therapy Market Estimates and Forecasts by Vector Type (2021-2032) (USD Billion)
11.6.9.4 Rest of Latin America Cancer Gene Therapy Market Estimates and Forecasts by End-User (2021-2032) (USD Billion)
12. Company Profiles
12.1 OncoGenex Pharmaceuticals Inc.,
12.1.1 Company Overview
12.1.2 Financial
12.1.3 Products/ Services Offered
12.1.4 SWOT Analysis
12.2 Merck KGaA,
12.2.1 Company Overview
12.2.2 Financial
12.2.3 Products/ Services Offered
12.2.4 SWOT Analysis
12.3 Introgen Therapeutics Inc.,
12.3.1 Company Overview
12.3.2 Financial
12.3.3 Products/ Services Offered
12.3.4 SWOT Analysis
12.4 GSK plc (GlaxoSmithKline)
12.4.1 Company Overview
12.4.2 Financial
12.4.3 Products/ Services Offered
12.4.4 SWOT Analysis
12.5 GenVec
12.5.1 Company Overview
12.5.2 Financial
12.5.3 Products/ Services Offered
12.5.4 SWOT Analysis
12.6 Genelux Corporation
12.6.1 Company Overview
12.6.2 Financial
12.6.3 Products/ Services Offered
12.6.4 SWOT Analysis
12.7 Elevate Bio Inc
12.7.1 Company Overview
12.7.2 Financial
12.7.3 Products/ Services Offered
12.7.4 SWOT Analysis
12.8 Celgene Inc.,
12.8.1 Company Overview
12.8.2 Financial
12.8.3 Products/ Services Offered
12.8.4 SWOT Analysis
12.9 Bluebird Bio Inc.,
12.9.1 Company Overview
12.9.2 Financial
12.9.3 Products/ Services Offered
12.9.4 SWOT Analysis
12.10 BioCancell Inc
12.10.1 Company Overview
12.10.2 Financial
12.10.3 Products/ Services Offered
12.10.4 SWOT Analysis
13. Use Cases and Best Practices
14. Conclusion
Key Segments:
By Indication
- Large B-Cell Lymphoma
-
Multiple Myeloma
-
Acute Lymphoblastic Leukemia (ALL)
-
Melanoma (lesions)
-
Others
By Route of Administration
-
Intravenous
-
Others
By Vector Type
-
Lentivirus
-
RetroVirus & gamma RetroVirus
-
AAV
-
Modified Herpes Simplex Virus
-
Adenovirus
-
Others
By End User
-
Cancer Research Institutes
-
Diagnostic Centers
-
Others (Hospitals and biotechnology Companies)
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
-
US
-
Canada
-
Mexico
Europe
-
Germany
-
France
-
UK
-
Italy
-
Spain
-
Poland
-
Turkey
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Singapore
-
Australia
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g., Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
